MLTX Quote, Financials, Valuation and Earnings

Kuros Biosciences Ltd. has a net margin of -- compared to MoonLake Immunotherapeutics's net margin of --. MoonLake Immunotherapeutics's return on equity of -63.29% beat Kuros Biosciences Ltd.'s return on equity of -6.35%.

MoonLake Immunotherapeutics has a consensus price target of $26.71, signalling upside risk potential of 53.88%. On the other hand Kuros Biosciences Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that MoonLake Immunotherapeutics has higher upside potential than Kuros Biosciences Ltd., analysts believe MoonLake Immunotherapeutics is more attractive than Kuros Biosciences Ltd..

MoonLake Immunotherapeutics has a beta of 1.194, which suggesting that the stock is 19.382% more volatile than S&P 500. In comparison Kuros Biosciences Ltd. has a beta of 1.022, suggesting its more volatile than the S&P 500 by 2.244%.

MoonLake Immunotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kuros Biosciences Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MoonLake Immunotherapeutics pays -- of its earnings as a dividend. Kuros Biosciences Ltd. pays out -- of its earnings as a dividend.

MoonLake Immunotherapeutics quarterly revenues are --, which are larger than Kuros Biosciences Ltd. quarterly revenues of --. MoonLake Immunotherapeutics's net income of -$63M is higher than Kuros Biosciences Ltd.'s net income of --. Notably, MoonLake Immunotherapeutics's price-to-earnings ratio is -- while Kuros Biosciences Ltd.'s PE ratio is 451.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MoonLake Immunotherapeutics is -- versus 7.47x for Kuros Biosciences Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

EvoNext Holdings SA has a net margin of -- compared to MoonLake Immunotherapeutics's net margin of --. MoonLake Immunotherapeutics's return on equity of -63.29% beat EvoNext Holdings SA's return on equity of --.

MoonLake Immunotherapeutics has a consensus price target of $26.71, signalling upside risk potential of 53.88%. On the other hand EvoNext Holdings SA has an analysts' consensus of -- which suggests that it could fall by --. Given that MoonLake Immunotherapeutics has higher upside potential than EvoNext Holdings SA, analysts believe MoonLake Immunotherapeutics is more attractive than EvoNext Holdings SA.

MoonLake Immunotherapeutics has a beta of 1.194, which suggesting that the stock is 19.382% more volatile than S&P 500. In comparison EvoNext Holdings SA has a beta of -34.970, suggesting its less volatile than the S&P 500 by 3597.022%.

MoonLake Immunotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. EvoNext Holdings SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MoonLake Immunotherapeutics pays -- of its earnings as a dividend. EvoNext Holdings SA pays out -- of its earnings as a dividend.

MoonLake Immunotherapeutics quarterly revenues are --, which are larger than EvoNext Holdings SA quarterly revenues of --. MoonLake Immunotherapeutics's net income of -$63M is higher than EvoNext Holdings SA's net income of --. Notably, MoonLake Immunotherapeutics's price-to-earnings ratio is -- while EvoNext Holdings SA's PE ratio is 5.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MoonLake Immunotherapeutics is -- versus 0.61x for EvoNext Holdings SA. Usually stocks with elevated PS ratios are considered overvalued.

BeOne Medicines Ltd. has a net margin of -- compared to MoonLake Immunotherapeutics's net margin of 4.44%. MoonLake Immunotherapeutics's return on equity of -63.29% beat BeOne Medicines Ltd.'s return on equity of 7.54%.

MoonLake Immunotherapeutics has a consensus price target of $26.71, signalling upside risk potential of 53.88%. On the other hand BeOne Medicines Ltd. has an analysts' consensus of $408.32 which suggests that it could grow by 31.38%. Given that MoonLake Immunotherapeutics has higher upside potential than BeOne Medicines Ltd., analysts believe MoonLake Immunotherapeutics is more attractive than BeOne Medicines Ltd..

MoonLake Immunotherapeutics has a beta of 1.194, which suggesting that the stock is 19.382% more volatile than S&P 500. In comparison BeOne Medicines Ltd. has a beta of 0.533, suggesting its less volatile than the S&P 500 by 46.676%.

MoonLake Immunotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BeOne Medicines Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MoonLake Immunotherapeutics pays -- of its earnings as a dividend. BeOne Medicines Ltd. pays out -- of its earnings as a dividend.

MoonLake Immunotherapeutics quarterly revenues are --, which are smaller than BeOne Medicines Ltd. quarterly revenues of $1.5B. MoonLake Immunotherapeutics's net income of -$63M is lower than BeOne Medicines Ltd.'s net income of $66.8M. Notably, MoonLake Immunotherapeutics's price-to-earnings ratio is -- while BeOne Medicines Ltd.'s PE ratio is 124.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MoonLake Immunotherapeutics is -- versus 6.63x for BeOne Medicines Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

Santhera Pharmaceuticals Holding AG has a net margin of -- compared to MoonLake Immunotherapeutics's net margin of --. MoonLake Immunotherapeutics's return on equity of -63.29% beat Santhera Pharmaceuticals Holding AG's return on equity of 276.68%.

MoonLake Immunotherapeutics has a consensus price target of $26.71, signalling upside risk potential of 53.88%. On the other hand Santhera Pharmaceuticals Holding AG has an analysts' consensus of -- which suggests that it could fall by --. Given that MoonLake Immunotherapeutics has higher upside potential than Santhera Pharmaceuticals Holding AG, analysts believe MoonLake Immunotherapeutics is more attractive than Santhera Pharmaceuticals Holding AG.

MoonLake Immunotherapeutics has a beta of 1.194, which suggesting that the stock is 19.382% more volatile than S&P 500. In comparison Santhera Pharmaceuticals Holding AG has a beta of -0.778, suggesting its less volatile than the S&P 500 by 177.839%.

MoonLake Immunotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Santhera Pharmaceuticals Holding AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MoonLake Immunotherapeutics pays -- of its earnings as a dividend. Santhera Pharmaceuticals Holding AG pays out -- of its earnings as a dividend.

MoonLake Immunotherapeutics quarterly revenues are --, which are larger than Santhera Pharmaceuticals Holding AG quarterly revenues of --. MoonLake Immunotherapeutics's net income of -$63M is higher than Santhera Pharmaceuticals Holding AG's net income of --. Notably, MoonLake Immunotherapeutics's price-to-earnings ratio is -- while Santhera Pharmaceuticals Holding AG's PE ratio is 1.45x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MoonLake Immunotherapeutics is -- versus 4.43x for Santhera Pharmaceuticals Holding AG. Usually stocks with elevated PS ratios are considered overvalued.